Cellyan Biotechnology (HKPD) Current Deferred Revenue (2024 - 2025)
Cellyan Biotechnology (HKPD) reported Current Deferred Revenue of $529008.0 for Q3 2025, up 552.17% year-over-year from $81114.5 in Q3 2024, and up 324.88% quarter-over-quarter from $124507.0 in Q1 2025.
Cellyan Biotechnology (HKPD) Current Deferred Revenue (2024 - 2025) Analysis & Trends
Cellyan Biotechnology (HKPD) has 2 years of Current Deferred Revenue data on file, last reported at $529008.0 in Q3 2025.
- Current Deferred Revenue for Q3 2025 came in at $529008.0, up 552.17% year-over-year; the trailing twelve-month figure through Sep 2025 was $529008.0 (up 552.17% YoY), and the FY2025 annual result was $124507.0, down 34.84% from the prior year.
- Current Deferred Revenue grew to $529008.0 in Q3 2025 per HKPD's latest filing, from $124507.0 in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $529008.0 in Q3 2025 and troughed at -$116992.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Akso Health | 2,315,158.81 Bn | 2,315,158.63 Bn | - |
| 2 | Mckesson | 92.76 Bn | 89.18 Bn | 4.04 Bn |
| 3 | Cencora | 52.82 Bn | 50.83 Bn | 3.59 Bn |
| 4 | Cardinal Health | 52.17 Bn | 48.39 Bn | 2.50 Bn |
| 5 | Henry Schein | 9.19 Bn | 9.71 Bn | 1.07 Bn |
| 6 | Accendra Health | 246.88 Mn | -90.00 Mn | 312.39 Mn |
| 7 | Edap Tms | 161.92 Mn | 146.92 Mn | 8.15 Mn |
| 8 | 111 | 107.47 Mn | 25.61 Mn | 23.58 Mn |
| 9 | Cosmos Health | 9.42 Mn | 7.26 Mn | 1.38 Mn |
| 10 | Cellyan Biotechnology | 5.69 | -2.48 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 529,008.00 |
| Mar 31, 2025 | 124,507.00 |
| Sep 30, 2024 | -116,992.00 |
| Mar 31, 2024 | 191,066.00 |